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StrainStatins are inhibitors of the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, thereby inhibiting
cell synthesis of cholesterol and isoprenoids. Moreover, several studies have been evaluating pleiotropic effects
of statins, mainly because they present neuroprotective effects in various pathological conditions. However,
knowledge about behavioral effects of statins per se is relatively scarce. Considering these facts, we aimed to an-
alyze behavioral responses of atorvastatin or simvastatin-treated mice in the open ﬁeld test, elevated plus maze
and object location test. Atorvastatin treatment for 7 consecutive days at 1mg/kg or 10mg/kg (v.o.) or simvastat-
in 10 mg/kg or 20 mg/kg enhanced cognitive performance in object location test when compared to control
group (saline-treated mice). Simvastatin effects on mice performance in the object location test was abolished
by post-training infusion of the beta-adrenoceptor antagonist propranolol. Atorvastatin and simvastatin did
not change the behavioral response in open ﬁeld and elevated plus-maze (EPM) tests in any of the used doses.
These data demonstrate the positive effects of both statins in cognitive processes in mice, without any alteration
in locomotor parameters in the open ﬁeld test or anxiolytic-like behavior in EPM. In conclusion, we demonstrate
that atorvastatin and simvastatin per se improve the cognitive performance in a rodent model of spatial memory
and this effect is related to beta-adrenergic receptors modulation.
© 2015 Elsevier Inc. All rights reserved.ação em Ciências Fisiológicas,
pe, São Cristóvão, SE, Brazil.1. Introduction
Statins are inhibitors of the enzyme 3-hydroxy-3-methylglutaryl-
coenzyme A (HMG-CoA) reductase, thereby inhibiting cell synthesis of
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maker enzyme of cholesterol synthesis by reducing HMG-CoA to
mevalonate [2]. Retrospective studies suggest that the prevalence of
Alzheimer Disease (AD) and vascular dementia is lower among patients
taking statins, even reducing the levels of Aβ peptides induced by cere-
bral trauma [3–5]. Additionally, several studies have evaluated pleiotro-
pic effects of statins, mainly because they present neuroprotective
effects on pathological conditions [6–8]. Furthermore, the safety of
high doses of atorvastatin and simvastatin has been demonstrated in
adult humans [9,10].
Several studies in rodent animals are performed to evaluate the neu-
roprotective effects of statins [11–14]. Statins promote reduction of
neurological deﬁcits and increase in synaptogenesis, angiogenesis and
neuronal survival in animals exposed to a model of traumatic brain in-
jury [15]. Atorvastatin reduced the seizure activity and the neuronal
death in rat hippocampus after seizures induced by kainate [1]. Atorva-
statin also reduced the number of convulsing animals and promoted
neuroprotection against hippocampal cell death after seizures induced
by quinolinic acid, an NMDA receptor agonist [8]. Other members of
the statin family, as ﬂuvastatin, simvastatin and pravastatin, have
shown differential effects regarding on the intervention schedule
against cognitive impairment induced by amyloid-beta (Aβ) peptide in-
fusion, due to a prevention of cholinergic neuronal loss ormodulation of
glutamatergic system [16,17].Moreover, clinical data indicates that stat-
in therapy is linked to a reduction in the incidence of depression and
anxiety [18], although themechanisms of action are not yet established.
Despite the evidence of important roles for statins on neurological
diseases, the knowledge about behavioral effects of statins per se is
scarce [19]. It has been demonstrated that treatment with statins
prevented spatial memory deﬁcit induced by traumatic brain injury or
scopolamine infusion in rodents [15,20,21]. Statin treatment has also
been shown to prevent neuronal cell death as well to prevent cognitive
deﬁcits induced by Aβ infusion [22,23]. Besides, it has been shown that
simvastatin treatment improved the performance of control rats in the
object location and passive avoidance tasks [14]. A wide range of
mechanisms has been proposed to explain these pleiotropic effects of
statins including antioxidant, anti-inﬂammatory, immunomodulatory,
modulation of nitric oxide production and increased expression of
brain-derived neurotrophic factor (BDNF) [24–26]. However, the
precise molecular mechanisms involved in the memory enhancing
effects of the statins remain unknown.
In this study,micewere subjected to three different behavioral tasks.
The open ﬁeld task (OF) represents a new environment and it is used to
analyze the locomotor behavior inmice and rats [27]. The elevated plus-
maze is the classical approach to evaluate anxiolytic-like behavior in
rats and currently is also used in mice [28]. The object location test
(OLT) is based on rodents' natural behavior (novelty preference), an
innate instinct that drives animals to learn about their environment
(discrimination ratio). Additionally, it has been reported that the
performance of animals in this task is dependent of the hippocampal
function [29].
Considering the necessity for elucidation of the behavioral effects of
statins, this study investigated the behavioral effects of atorvastatin and
simvastatin treatments inmice submitted to the OF, EPM and OPR tests.
Additionally, we evaluated the involvement of beta-adrenergic receptor
on the cognitive effects of statin treatment.
2. Materials and methods
2.1. Animals
Male adult Swiss albinomice (3months old/45 ± 5 g) were kept on
a 12-h light/dark cycle (light on at 07.00 a.m.) at a constant temperature
of 22±1 °C. Theywere housed in plastic cageswith tapwater and com-
mercial food ad libitum. All procedureswere carried out according to the
institutional policies on animal experimental handling, designed tominimize suffering and limit the number of animals used and were
approved by the local Ethical Committee for Animal Research. All exper-
iments were performed during the light phase (between 14:00 and
17:00 h) to avoid circadian variations.
2.2. Pharmacological treatments
Total of 203 male Swiss albino mice were employed to study the
putative role of statins on behavioral changes, animals were treated
orally with atorvastatin (Lipitor Atorvastatin calcium, Pﬁzer) 0.1, 1 or
10 mg/kg/day, or simvastatin 1, 10 or 20 mg/kg/day once a day during
seven consecutive days [7,8]. Control animals were treated with vehicle
(NaCl 0.9%) orally for the same period. One day after the last atorvastat-
in or saline administration animals were submitted to the speciﬁcally
behavioral task. Object location test, or open ﬁeld, or elevated plus
maze were analyzed in this speciﬁc time.
After the initial results, we performed additional experimental
procedure to evaluate the involvement of beta-adrenergic receptors in
the effects of statins in the OLT (49 animals were employed in these
experiments). Mice received 10 mg/kg/day of simvastatin or vehicle
(NaCl 0.9%) for seven days. One day after the last simvastatin or vehicle
(NaCl 0.9%) animals were submitted to OLT. The animals of two initial
groups were treated with the beta-adrenergic receptor antagonist pro-
pranolol (2 mg/kg, i.p.; Sigma Chemical Co., St. Louis, U.S.A.) or vehicle
(NaCl 0.9%) immediately after the training session. All treatments
were done by the administration of 10 μl/g weight of the animal.
2.3. Behavioral tasks
Mice were randomly assigned for treatments. Animals were housed
in the communal plastic cages (10 animals per cage). The behavioral
task was performed and analyzed by a blinded observer. Every experi-
mental procedure presents animals of each group to comparative anal-
yses. A control experiment procedure was used by two groups to
evaluate the effects of propranolol in short termmemory of Swiss albino
mice in OLT. All experiments were performed during the light phase
(between 14:00 and 17:00 h) to avoid circadian variations. In every
experiment, the animals are exposed to apparatus in randomized
order to minimize the circadian effects in the behavioral analyses.
2.4. Object location test
The OLT was performed in an apparatus consisting of a wooden box
chamber (40 cm × 60 cm × 50 cm). Before the experimental sessions,
animals (total of 112, distributed in 4 experiments) were habituated
to the experimental room for 90 min in dim light conditions. A light
bulbwas switched on during the experimental sessions. The light inten-
sity was equal in different parts of the apparatus. In the adaptation ses-
sions, mice explored the apparatus for 10 min, with no object. The
objects were placed equidistant from two corners, 10 cm apart from
the wall. Mice were placed individually into the chamber and per-
formed the task for 10 min. In training sessions, 2 similar objects were
utilized. In test sessions, performed 90 min (12 animals, to control the
effects of propranolol in short term memory) or 24 h later (total of
100 animals), one object was replaced to the other corner of the cham-
ber. The objects employedwere two LEGO® pieces presenting the same
texture, size, shape and color. The objects were not known to have any
ethological signiﬁcance for mice [30]. Discrimination ratio was
expressed by the ratio TN/(TN + TF), (TN, time spent exploring the
novel place; TF, time spent exploring familiar place), both in the training
and test sessions. During the inter-trial interval objects were cleaned
with 10% ethanol solution to avoid odor cues. Exploration was deﬁned
by directing the nose to the object at a distance less than 2 cm and/or
touching the object with the nose or forepaws. The time of exploration
wasmeasured by two blinded observers, with the use of chronometers.
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ed from the study [30].
2.5. Open ﬁeld (OF)
To examine the effect of atorvastatin treatment on spontaneous
locomotor activity, the animals (64 mice) were placed for 5 min in the
open ﬁeld arena. The apparatus, a transparent Plexiglas arena
(30 × 30 × 15 cm), had a black Plexiglas ﬂoor divided by white lines
in nine squares (10 cm × 10 cm). The experiments were conducted in
a sound-attenuated room and light intensity in the center of the appara-
tus was 110 lx. The animals were placed in the center of the open ﬁeld
and the movement of each mouse was recorded using a video camera
placed above the open ﬁeld apparatus. The recorded movements were
then analyzed using ETHOWATCHER(®) system [31] and the numbers
of squares crossed, rearing behavior, distance traveled and velocity
performed were calculated.
2.6. Elevated plus-maze test (EPM)
The EPM was made of clear Plexiglas and consisted of two opposed
open arms (30 × 5 × 0.25 cm) and two opposed closed arms
(30 × 5 × 15 cm), all extending from a central platform (5 × 5 cm), el-
evated 45 cm from the ﬂoor. The apparatus was placed in a small closed
room lit by a 15 W red light. The animals (76 mice) were placed in the
central platform, facing an enclosed arm, and were observed for a
5 min period. The entries into either arms (open or closed), as well as
the time spent in each arm type were recorded (in sec). The ratios
“time spent in the open arms/time spent in all (i.e. open plus closed)
arms” and “frequency of entries into open arms/total entries into all
arms” were calculated and multiplied by 100, to yield the percentage
of time spent in and of frequency of entries into open arms, respectively.
Both parameters are considered to reﬂect fear-induced inhibition from
entering the open arms, and drugs with anxiolytic activity usually in-
crease the time spent in and/or entries into open arms, whereas the re-
verse holds true for anxiogenic-like drugs. Furthermore, the number of
entries into enclosed arms was used as an index of general activity [32].
2.7. Statistical analyses
One-sample t tests were used to determine whether the location
index was different from chance performance (50%) in the OLT. For
the other behavioral data, comparisons among treatment groups and
control were performed by one-way or two-way ANOVA, followed by
Newman–Keuls test when appropriate. A value of p b 0.05 was consid-
ered to be signiﬁcant in all tests.
3. Results
3.1. Object location test
In the OLT, control group (t= 1.14, p= 0.19) (0.48± 0.03) or ator-
vastatin 0.1mg/kg/day treatment (t= 0.2, p=0.84) (0.51± 0.13) pre-
sented location index that did not differ from chance performance,
indicating that mice in these groupswere not able to identify the spatial
alteration in this task (Fig. 1A). However, mice treatedwith atorvastatin
1 mg/kg/day (t = 4.11, p b 0.01) ((0.6 ± 0.07) or 10 mg/kg/day (t =
3.34; p b 0.01) (0.59 ± 0.09) have shown a location index signiﬁcantly
increased from chance performance (Fig. 1A). One-way ANOVA follow-
ed by Newman–Keuls post-hoc test indicated that atorvastatin 1 or
10 mg/kg/day treatment is signiﬁcantly different from control group
[F(3,30) = 4.26; p b 0.05] (Fig. 1A). Location index of mice treated
with saline (t = 1.77; p = 0.11) (0.46 ± 0.06) or simvastatin
1mg/kg/day (t= 0.11; p= 0.91) (0.5± 0.2) did not differ from chance
performance (Fig. 1C). Mice treated with simvastatin 10 (0.62 ± 0.03)
or 20 mg/kg/day (0.62 ± 0.11) presented location indexes increasedfrom chance performance, (t = 2.4; p = 0.03 and t = 3.1, p = 0.02, re-
spectively) (0.62 ± 0.03; 0.62 ± 0.11) (Fig. 1C). Furthermore, one-way
ANOVA followed byNewman–Keuls post-hoc test indicated that simva-
statin treatment 10 or 20 mg/kg/day are signiﬁcantly different from
control group [F(3,26) = 4.31; p b 0.05] (Fig. 1C).
As revealed by two-way ANOVA, all groups presented a similar time
spent in both objects in the training and test sessions [atorvastatin:
F(3,30) = 0.32; p = 0.8], [simvastatin: F(3,26) = 0.17; p = 0.91] and
the same decrease in time spent in both objects in the test session [ator-
vastatin: F(3,30) = 72.49; p b 0.05] and [simvastatin: F(3,26) = 32.13;
p b 0.05] (Fig. 1B and D). In atorvastatin experiments, time spent in both
objects in training and test sessions are, respectively: control group
(58.32 ± 25.3; 22.85 ± 9.89), atorvastatin 0.1 mg/kg (50.5 ± 11.48;
19.83 ± 7.27), atorvastatin 1 mg/kg (58.26 ± 30.34; 26.72 ± 14.83)
and atorvastatin 10mg/kg (58.12±21.56; 19.62±5.85). In simvastatin
experiments, time spent in both objects in training and test sessions are,
respectively: control group (36.36± 12.13; 22.66± 11.61), simvastatin
1 mg/kg (33.33 ± 5; 23.33 ± 8.98), simvastatin 10 mg/kg (35.38 ±
9.91; 20.87 ± 10.31) and simvastatin 20 mg/kg (39.42 ± 14.08;
22.63 ± 11.36).
A large body of evidence suggests that beta-adrenergic receptormay
modulate learning and memory processes evaluated in the passive
avoidance, water maze, object recognition and object location tests
[33–35]. To evaluate the involvement of beta-adrenergic receptors in
the effects of statins in the OLT, mice were treated with the beta-
adrenergic receptor antagonist propranolol immediately after the
training session. Fig. 2A shows that both vehicle (t = 2.97; p b 0.05)
(0.63 ± 0.1) or propranolol (2 mg/kg) (t = 3.21; p b 0.05) (0.61 ±
0.08) treated mice were able to discriminate the spatial alteration
when tested 90 min after the training session. This indicates that pro-
pranolol (2 mg/kg) did not interfere with consolidation of short-term
memory in the OLT.
As indicated in Fig. 2B, treatment with propranolol immediately
after training session prevented the increase in the location index in-
duced by simvastatin in theOLT. One-sample t-test revealed that simva-
statin group presented location index higher than chance performance
(t = 2.39; p b 0.05) (0.62 ± 0.14), while control group (t = 1.43;
p = 0.18) (0.43 ± 0.15), propranolol group (t = 1.05; p = 0.32)
(0.43 ± 0.17) and propranolol + simvastatin group (t = 1.54; p =
0.28) (0.54 ± 0.1) presented location indexes with no difference from
chance performance. The two-way ANOVA revealed signiﬁcant differ-
ence for simvastatin treatment [F(1,30)=11.68; p b 0.01], but nodiffer-
ence for propranolol treatment [F(1,30) = 1.21; p = 0.26] and
simvastatin–propranolol interaction [F(1,30) = 1.47; p = 0.23]
(Fig. 2B).
3.2. Open-ﬁeld
The administration of atorvastatin (0.1–10 mg/kg) or simvastatin
(1–20 mg/kg) did not affect mice exploration in the open ﬁeld test
(number of crossings after atorvastatin treatment: F(3,28) = 2.33,
p = 0.09; (72.13 ± 15.99; 83.13 ± 20.51; 94 ± 15.51; control group:
74.88 ± 20.15); number of rearings after atorvastatin treatment:
F(3,28) = 2.04, p = 0.13; (25.25 ± 6.36; 25.25 ± 9.67; 32.75 ± 6.08,
control group: 24.88 ± 7.53); number of crossings after simvastatin
treatment: F(3,28) = 1.91, p = 0.33 (71.13 ± 20.39; 85.56 ±
11.71; 77.71 ± 13.38; control group 79.63 ± 16.66); number of
rearings after simvastatin treatment: F(3,28) = 1.67, p = 0.19;
(26.38 ± 11.38; 32.89 ± 5.37; 28.71 ± 4.42; control group:
33.38 ± 6.36) (Fig. 3).
3.3. Elevated plus-maze test (EPM)
Fig. 4A–C shows that treatment with atorvastatin (0.1–10 mg/kg)
did not alter the percentage of time spent in the open arms
[F(3,31) = 0.47; p = 0.7] (12.77 ± 8.85; 11.12 ± 9.53; 16.37 ± 9.88;
Fig. 1. Effects of statin treatment onmice performance in the object location test. The animals were treated with vehicle (saline 0.9%, v.o.), atorvastatin (0.1–10.0mg/kg/day, v.o.) or sim-
vastatin (1–20mg/kg/day, v.o.) for seven days. Behavioral analysiswas performed 24 h after the last day of statin treatment. Micewere allowed to explore two identical objects for 10min
on the acquisition trial. The test trialwas conducted 24h after the acquisition trial. A: Effect of atorvastatin treatment on object location inmice. B: Time spent exploring both objects during
training and test sessions after atorvastatin treatment. C: Effect of simvastatin treatment on object location inmice. D: Time spent exploring both objects during training and test sessions
after simvastatin treatment. Results are presented asmeans± S.E.M. N=6–10 per group. *p b 0.05 versus chance level (% 50 of displaced object investigation in test trial). #p b 0.05 versus
control group. †p b 0.05 versus training session. ANOVA followed by Newman–Keuls post hoc test.
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[F(3,31) = 0.12; p = 0.94] (25.22 ± 16.66; 23.22 ± 10.53; 25.45 ±
7.37; control group: 27.45 ± 19.24) or total arms entries [F(3,31) =
2.04; p = 0.12] (12.75 ± 2.12; 12.88 ± 3.44; 17.38 ± 5.15;
control group: 14 ± 5.15) in the EPM. Similarly, simvastatin treatment
(1–20 mg/kg) did not promote any alteration the percentage of timeFig. 2. Effects of propranolol treatment on the cognitive effect of simvastatin in the object loca
(10 mg/kg/day, v.o.) for seven days. Behavioral analysis was performed 24 h after the last day
acquisition trial. Immediately after the training sessionmicewere injectedwith propranolol (2
of propranolol treatment on object location test inmicewith 90min intertrial interval. B: Effect
test inmice. Results are presented asmeans± S.E.M. N= 6–9 per group. *p b 0.05 versus chan
Two-way ANOVA followed by Newman–Keuls post hoc test.spent in the open arms (7.31 ± 5.13; 11.33 ± 8.45; 11.67 ± 9.22;
control group: 12.52 ± 9.21) [F(3,37) = 0.59; p = 0.62], percentage
of entries in the open arms (19.5 ± 9.6; 23.76 ± 13.15; 22.3 ± 14.9;
control group: 26.97 ± 11.19) [F(3,37) = 0.54; p = 0.65] or total
arms entries (12.43 ± 2.07; 13.17 ± 4.34; 13.36 ± 4.38; control
group: 14 ± 5.15) [F(3,37) = 0.19; p = 0.89] in the EPM (Fig. 4D–F).tion test in mice. The animals were treated with vehicle (saline 0.9%, v.o.) or simvastatin
of statin treatment. Mice were allowed to explore two identical objects for 10 min on the
mg/kg, i.p.). The test trial was conducted 90min or 24 h after the acquisition trial. A: Effect
of propranolol treatment on the simvastatin induced cognitive effect in the object location
ce level (% 50 of displaced object investigation in test trial). #p b 0.05 versus control group.
Fig. 3.Effects of statin treatment in the openﬁeld test. The animalswere treatedwith vehicle (saline 0.9%, v.o.), atorvastatin (0.1–10.0mg/kg/day, v.o.) or simvastatin (1–20mg/kg/day, v.o.) for
seven days. Behavioral analysis was performed 24 h after the last day of statin treatment. A: Number of crossings in the open ﬁeld after atorvastatin treatment. B: Number of rearings in the
open ﬁeld after atorvastatin treatment. C: Number of crossings in the open ﬁeld after simvastatin treatment. D: Number of rearings in the open ﬁeld after simvastatin treatment. N=8–9 per
group. One-way ANOVA.
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In the present study, we demonstrated that mice treated with ator-
vastatin or simvastatin was able to discriminate the spatial alteration
in the OLT for a long period than vehicle-treatedmice. The effect of sim-
vastatin treatment on mice performance in the OLT was abolished by
beta-adrenergic receptor blockade with propranolol, suggesting that
at least in part this mnemonic effect involves the beta-adrenergic
system. Besides, we demonstrated that treatment with atorvastatin or
simvastatin did not promote any change in individual performance in
exploratory- and anxiety-like tasks in Swiss mice. These ﬁndings
demonstrated that short treatment of atorvastatin and simvastatin
per se promoted an improvement in cognitive response, besides the cel-
lular protective effects that has been previously demonstrated in animal
models of neurological disorders.
It has been shown that atorvastatin is able to promote improvement
in the consolidation and retrieval phases of memory [21]. Moreover,
atorvastatin (5 mg/kg) is also able to protect the deﬁcit in the spatial
recognition performance in mice treated with scopolamine [21]. We
demonstrated that treatment with atorvastatin (1 or 10 mg/kg) and
simvastatin (10 or 20mg/kg) for 7 days, promoted a cognition improve-
ment ofmice in theOLT, however, low doses of atorvastatin (0.1mg/kg)
and simvastatin (1 mg/kg) did not improve the cognition performance.
Simvastatin has been shown to improve the performance of
Sprague–Dawley rats in object location and in inhibitory avoidance
tests [14]. Additionally, simvastatin enhanced LTP in the hippocampus,
a region involved in the learning/memory process in these tasks [36].
However, it is important to mention that prolonged treatment withstatins may occasionally promote adverse effects such as liver toxicity
andmyopathy [37,38]. Despite different periods of treatment, both ator-
vastatin and simvastatin have been shown to promote a decrease in de-
generation of hippocampal neurons and to improvement in short-term
and long-term functional performances after traumatic brain injury in
mice [39].
Both statin treatments did not elicit any changes in open ﬁeld and el-
evatedplus-maze exploration. In accordance to this, Ludka et al. demon-
strated that a single administration of atorvastatin in a range dose of
0.01 to 30 mg/kg, did not cause any changes in locomotor parameters
[40]. It has been shown that 1 week of atorvastatin treatment (10 and
20 mg/kg) improved the deﬁcit promoted by stroke in the locomotors
patterns, but atorvastatin per se did not cause any changes in OF [41].
The literature demonstrates that 2 weeks of simvastatin treatment
do not change exploratory patterns in open ﬁeld in rats, however 4
weeks of simvastatin (10 mg/kg) treatment promotes an increase
in distance traveled in the open ﬁeld task [14,19]. Moreover, 4
weeks of simvastatin treatment increased the time spent exploring
open arms in EPM, reﬂecting a reduction in anxiety-like behavior
[19]. Additionally, it has been demonstrated that 8 weeks of simva-
statin treatment improves motor coordination on the rotarod,
while slowing down motor speed on the horizontal bar of the coat-
hanger [42]. In fact, the behavioral responses to statin treatment de-
pend on time of treatment and on the statin employed. Therefore, 7
days of treatment of atorvastatin or simvastatin did not alter the lo-
comotor parameters here evaluated.
Atorvastatin and simvastatin induce neurogenesis and improve spa-
tial learning after traumatic brain injury [43]. In addition, atorvastatin is
Fig. 4. Effects of atorvastatin treatment in the elevated plus-maze test. The animals were treated with vehicle (saline 0.9%, v.o.), atorvastatin (0.1–10.0 mg/kg/day, v.o.) or sim-
vastatin (1–20 mg/kg/day, v.o.) for seven days. Behavioral analysis was performed 24 h after the last day of statin treatment. A: Percentage of time spent in the open arms (% open arm
time) after atorvastatin treatment. B: Percentage of number of entries into open arms (% open arms entry) after atorvastatin treatment. C: Total arms entries after atorvastatin treatment
(total entries). D: Percentage of time spent in the open arms after simvastatin treatment. E: Percentage of number of entries into open arms after simvastatin treatment. F: Total arms
entries after simvastatin treatment. Values expressed are as mean ± S.E.M. One-way ANOVA.
32 S. Vandresen-Filho et al. / Physiology & Behavior 143 (2015) 27–34able to promote an improvement in consolidation and retrieval phases
of memory in a Y maze task, although nitric oxide (NO) is involved in
atorvastatin effect in the consolidation but not in retrieval phase of
memory [21]. Ludka et al. demonstrated that an acute treatment with
atorvastatin in low doses improved BDNF protein levels in the hippo-
campus of Swiss albinomice [40]. BDNF has multiple effects on sustain-
ing and evoking elements of brain plasticity and it is involved in the
mnemonic process [44]. Therefore, statins present cognitive effects on
animals and, at least in part, these effects might be related to a modula-
tion of BDNF expression and nitric oxide synthesis, although the exactmechanisms by which statins promote cognitive improvement need
to be further explored.
It has been proposed that the activation of β-adrenergic receptors is
an important link between NO synthesis and expression of genes in-
volved in the learning process, such as BDNF [45]. In this way, since
NO signaling pathway and BDNF expression have been related to the
beneﬁcial effects of statins, we aimed to evaluate if statin effect could
be abolished by noradrenergic beta-receptor blockade. Our ﬁndings
demonstrated that propranolol administered immediately after training
disrupted the effect of simvastatin in the location memory test. It is
33S. Vandresen-Filho et al. / Physiology & Behavior 143 (2015) 27–34known thatβ-adrenergic receptor blockade impairs the consolidation of
memory training experiences both in aversive tasks [46] and tasks in-
volving low levels of emotional arousal, such as novel object recognition
[47,48]. Moreover, it has been demonstrated that the noradrenergic
system of basolateral amygdala modulates long-term memory
consolidation of object-in-context recognition training [49]. Besides
the effects on beta-adrenergic system, statin treatment has also been
shown to modulate alpha noradrenergic receptors. Kandasamy et al.
demonstrated that atorvastatin treatment prevented hyporreactivity
to noradrenalin in the aorta from septic mice in part by increasing
α(1D)-adrenoceptor mRNA expression [50]. In fact, other G-protein
coupled receptors have been implicated in the pleiotropic effects of
statins. Atorvastatin antidepressant-like effect in the tail suspension
test has been shown to be dependent on 5-HT1A/2A/C receptor
modulation [51]. However, the exact mechanism through which statins
modulate G-protein coupled receptors, such as noradrenergic and sero-
tonergic receptors remains unclear.
Nevertheless, few articles demonstrate the direct interaction be-
tween statin treatment and beta-adrenergic receptors in the central
nervous system. In cardiac tissue, Clements and Jamali [52] demon-
strated that 4 days of pravastatin 6 mg/kg (twice day) improve the
potency of propranolol to prolong PR interval, the authors suggest that
the interaction effects of statin and propranolol occur at the pharmaco-
dynamic level because pravastatin did not inﬂuence the pharmacoki-
netics of propranolol. Additionally, pravastatin 6 mg/kg (twice a day)
did not change the binding of propranolol to plasma proteins
(Clements and Jamali, 2007). It may be possible that statin treatment
modulates beta-adrenergic receptors directly through the modulation
of isoprenylation of Gγ subunits and/or indirectly through modulation
of intracellular signaling pathways [53]. In fact, statins appear to reverse
the down-regulatory effect of inﬂammation on β-adrenergic receptors
[54]. Therefore, one interesting point to be elucidated is the direct
and/or indirect interactions between statins and β-adrenergic receptor
activity.
In conclusion, atorvastatin or simvastatin treatment for 7 days pre-
sented beneﬁcial effects on learning and memory in mice in the object
location test. Furthermore, both statin treatments for 7 days do not
change the exploratory behavior in open ﬁeld and elevated plus-maze,
suggesting no collateral effects that could impair a short treatment
with atorvastatin and simvastatin. Additionally, the effect of simvastatin
on mice performance in the OLT involves, at least partially, the beta-
adrenergic system. However, more studies are necessary to elucidate
themechanisms throughwhich statinsmodulate themnemonic events.
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